Hyo Sook Han MD

Oncology•Tampa, FL

Breast Cancer

Senior member, Research Director

Request Appointment

12902 Usf Magnolia DrTampa, FL 33612
Book by Phone+1(563) 362-9232

Education & Training

University of Miami/Jackson Health SystemFellowship, Hematology and Medical Oncology, 2005 - 2008
Cleveland Clinic FoundationResidency, Internal Medicine, 2002 - 2005
Seoul National University College of MedicineClass of 1999

Certifications & Licensure

FL State Medical License 2008 - 2026
CA State Medical License 2004 - 2022
OH State Medical License 2002 - 2005
American Board of Internal Medicine Medical Oncology

Clinical Trials

A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation Start of enrollment: 2012 Aug 01
Completed
Phase 2, Phase 3
A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi Start of enrollment: 2012 Oct 03
Terminated
Phase 3
A Phase I Dose Escalation Study of Eribulin Plus Weekly Carboplatin for Metastatic Breast Patients Start of enrollment: 2013 Feb 06
Completed
Phase 1
COGNUTRIN in Breast Cancer Survivors Start of enrollment: 2014 Jul 30
Completed
Early Phase 1
Yoga for Aromatase Inhibitor-associated Joint Pain Start of enrollment: 2013 Sep 01
Completed
Not Applicable
Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer Start of enrollment: 2014 Sep 05
Completed
Phase 1, Phase 2
Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases Start of enrollment: 2014 Oct 09
Terminated
Phase 1
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC) Start of enrollment: 2017 Feb 02
Terminated
Phase 2
Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer Start of enrollment: 2018 Feb 19
ACTIVE_NOT_RECRUITING
PHASE2
Phase 2 Trial of Selinexor (KPT-330) for Metastatic Triple Negative Breast Cancer (TNBC) Start of enrollment: 2015 Jul 08
Completed
Phase 2
Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer Start of enrollment: 2017 Jun 23
Completed
Phase 1, Phase 2
Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation Start of enrollment: 2021 Sep 08
RECRUITING
PHASE1
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer Start of enrollment: 2010 Mar 01
RECRUITING
PHASE2
Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases Start of enrollment: 2021 Nov 30
RECRUITING
PHASE1, PHASE2
Join now to see all

Publications & Presentations

PubMed

Sacituzumab govitecan and stereotactic radiosurgery in the management of HER2 negative breast cancer brain metastases: a multi-institutional report.
Vaseem M Khatri, Mariella A Mestres-Villanueva, Sierra Daniel, Sreenija Yarlagadda, Ajay Doniparthi
Journal of Neuro-Oncology. 2025-12-01
Quantitative habitat concentration analysis of triple negative breast cancer on MRI correlates with pathologic response to combination neoadjuvant immuno/chemotherapy.
R Jared Weinfurtner, Dana Ataya, Kimberly Funaro, Asha Bhatt, Mahmoud Abdalah
Clinical Imaging. 2025-11-01
Gedatolisib Combined with Palbociclib and Letrozole in Patients with No Prior Systemic Therapy for Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer.
Robert Wesolowski, Hope S Rugo, Jennifer M Specht, Hyo S Han, Peter Kabos
Clinical Cancer Research. 2025-10-01

Lectures

SGNLVA-002: Single-arm, open label phase Ib/II study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of patients with unresect...
ASCO Annual Meeting 2019 - Chicago, IL - 6/2/2019

Press Mentions

Intratumoral Dendritic Cell Therapy Shows Promise in Early-Stage ERBB2-Positive Breast CancerDecember 9th, 2024
Vaccinex and Its Collaborators Present Two Abstracts Related to Pepinemab Combination Immunotherapy Trials at 37th Annual Meeting of Society for Immunotherapy of CancerNovember 10th, 2022